Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Pre-clinical research

Diabetes drug is activated by light to cause pancreas to release insulin

Blue light causes a modified version of glimepiride to act on ion channels in pancreatic islet cells to stimulate insulin release.

Molecular structure of glimepiride, a diabetes drug which is activated by light and causes the pancreas to release insulin

Source: Wikimedia Commons

The diabetes drug glimepiride (pictured) has been modified to include an azobenzene ring to create JB253, a prototype drug that responds to light

Scientists have developed a “photoswitchable” version of the diabetes drug glimepiride that is activated through exposure to blue light, allowing insulin release by pancreatic cells to be optically controlled.

The prototype drug, known as JB253, is an azosulfonylurea compound – a standard sulfonylurea drug (glimepiride) that has been modified to include an azobenzene ring.

In the presence of blue light, this chemical element changes shape, causing the drug to interact with its receptor and exert its biological effect – namely, to act on ion channels in pancreatic islet cells to stimulate insulin release. When JB253 was administered to rodent or human pancreatic islet cells in vitro, application of blue light caused near-instantaneous insulin release, which ceased within milliseconds when the light source was removed.

The drug was developed by an international team based at the Department of Medicine at Imperial College London and Ludwig Maximilian University of Munich. The development of the drug and proof-of-concept study is reported in Nature Communications[1].

The researchers plan to give JB253 to mice; other azosulfonylurea drugs are also in development. Initially, the team will try to activate the drug in vivo using external, high-intensity LEDs (light-emitting diode); if this fails, they plan to implant fibre optics into the animals.

Researcher David Hodson, from Imperial College London, says that while the technology is still at a very early stage, it has the potential to overcome limitations associated with current diabetes therapy. “In principle, this type of therapy may allow better control over blood sugar levels because it can be switched on for a short time when required after a meal,” he says. “It should also reduce complications by targeting drug activity to where it’s needed in the pancreas.”

However, Hodson stresses that photoswitchable diabetes drugs are at least 5–10 years away from being available to patients. Many questions remain unanswered, including issues of safety, pharmacodynamics and how to target the light source to the pancreas. “Nonetheless, we believe that our new drug demonstrates that photopharmacology may one day be useful for the treatment of metabolic diseases such as type 2 diabetes,” he says.

Photoswitchable drugs could be valuable in other areas of medicine. A molecule known as AAQ is about to enter clinical trials as a treatment for retinitis pigmentosa. AAQ works by causing normally “blind” cells in the retina to become sensitive to light, thereby potentially taking the place of dysfunctional rods and cones.

A light-sensitive antibiotic is also in development, which is inactive until it is exposed to ultraviolet light. Such a drug could circumvent the issue of drug resistance caused by existing antibiotics that are excreted unmetabolised and therefore collect in the environment.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066857

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.